Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 15;8(12):22246-53.
eCollection 2015.

The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis

Jianhua Li  1 , Shuijun Zhang  1 , Shouhua Zheng  1 , Danhua Zhang  1 , Xinguang Qiu  1
Affiliations

The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis

Jianhua Li et al. Int J Clin Exp Med. .

Abstract

Introduction: There have been contradictory data on whether or not BRAF V600E mutation should be regard as a poor prognosis predictor of papillary thyroid carcinoma (PTC). To settle down the conflict, this metaanalysis is prepared to clarify the present prognostic role of BRAF V600E mutation in patients with PTC.

Methods and materials: The relevant published researches were incorporated according to the defined inclusion/exclusion criteria from PubMed. The effect sizes of outcome parameters were estimated by hazard ratios (HRs).

Results: The current meta-analysis included 19 researches with a total of 6087 patients. We have found that patients with BRAF V600E mutation have a poor overall survival (the pooled HR=2.91, 95% confidence interval (CI): 1.35-6.29). Furthermore, subgroup analysis of the recurrence-free survival (RFS) of PTC patients by races indicated that BRAF V600E mutation predicts poor RFS of patients (the pooled HR=1.63, 95% CI: 1.37-1.93), both Caucasian (the pooled HR=1.57, 95% CI: 1.30-1.90) and Asian (the pooled HR=1.91, 95% CI: 1.28-2.87).

Conclusions: The poor prognosis predicted role of BRAF V600E mutation in PTC was certified from the current meta-analysis. The BRAF V600E mutation may be used as a prognostic predictor of patients with PTC.

Keywords: BRAF V600E mutation; Thyroid; meta-analysis; thyroid papillary carcinoma (PTC).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reference filtration procedures of the present meta-analysis.
Figure 2
Figure 2
The pooled hazard ratio (HR, 95% CI) between the BRAF V600E mutation and overall survival (OS) of PTC patients.
Figure 3
Figure 3
The pooled hazard ratio (HR, 95% CI) between the BRAF V600E mutation and relapse-free survival (RFS) of PTC patients, based on subgroup analysis of races (Asian and Caucasian).
Figure 4
Figure 4
The Begg’s funnel plot revealed little publication bias between the included references.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306. - PubMed
    1. Neuhold N, Schultheis A, Hermann M, Krotla G, Koperek O, Birner P. Incidental papillary microcarcinoma of the thyroid-further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol. 2011;18:3430–3436. - PubMed
    1. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–762. - PubMed
    1. Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559–4570. - PMC - PubMed

LinkOut - more resources